{"protocolSection": {"identificationModule": {"nctId": "NCT02066298", "orgStudyIdInfo": {"id": "AsthmaNet 007"}, "secondaryIdInfos": [{"id": "1U10HL098115", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1U10HL098115"}], "organization": {"fullName": "Milton S. Hershey Medical Center", "class": "OTHER"}, "briefTitle": "Steroids In Eosinophil Negative Asthma", "officialTitle": "Steroids In Eosinophil Negative Asthma", "acronym": "SIENA"}, "statusModule": {"statusVerifiedDate": "2019-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-10", "studyFirstSubmitQcDate": "2014-02-17", "studyFirstPostDateStruct": {"date": "2014-02-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-03-28", "resultsFirstSubmitQcDate": "2019-03-28", "resultsFirstPostDateStruct": {"date": "2019-04-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-05-16", "lastUpdatePostDateStruct": {"date": "2019-05-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "dave mauger", "investigatorTitle": "Principal Investigator, AsthmaNet Data Coordinating Center", "investigatorAffiliation": "Milton S. Hershey Medical Center"}, "leadSponsor": {"name": "Milton S. Hershey Medical Center", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Because approximately half of all mild-moderately-severe asthma is persistently non-eosinophilic, it is important to determine prospectively if patients who are persistently non-eosinophilic differ in their benefit from inhaled corticosteroid treatment compared to patients who are not persistently non-eosinophilic.", "detailedDescription": "SIENA is a 42-week randomized, stratified, 3-period double-blind placebo-controlled crossover study of patients with symptomatic mild-to-moderate asthma, not already taking an inhaled corticosteroid, in whom the effect of \"medium-dose\" inhaled corticosteroid (ICS) will be compared with the effect of placebo and with a long-acting muscarinic antagonist (LMA)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Mometasone", "Tiotropium"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 295, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Mometasone then Tiotropium then Placebo", "type": "EXPERIMENTAL", "description": "Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo", "interventionNames": ["Drug: Mometasone 220mcg BID", "Drug: Tiotropium Respimat 5mcg QD", "Drug: Placebo"]}, {"label": "Mometasone then Placebo then Tiotropium", "type": "EXPERIMENTAL", "description": "Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD", "interventionNames": ["Drug: Mometasone 220mcg BID", "Drug: Tiotropium Respimat 5mcg QD", "Drug: Placebo"]}, {"label": "Placebo then Mometasone then Tiotropium", "type": "EXPERIMENTAL", "description": "Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD", "interventionNames": ["Drug: Mometasone 220mcg BID", "Drug: Tiotropium Respimat 5mcg QD", "Drug: Placebo"]}, {"label": "Placebo then Tiotropium then Mometasone", "type": "EXPERIMENTAL", "description": "Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID", "interventionNames": ["Drug: Mometasone 220mcg BID", "Drug: Tiotropium Respimat 5mcg QD", "Drug: Placebo"]}, {"label": "Tiotropium then Placebo then Mometasone", "type": "EXPERIMENTAL", "description": "Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID", "interventionNames": ["Drug: Mometasone 220mcg BID", "Drug: Tiotropium Respimat 5mcg QD", "Drug: Placebo"]}, {"label": "Tiotropium then Mometasone then Placebo", "type": "EXPERIMENTAL", "description": "Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo", "interventionNames": ["Drug: Mometasone 220mcg BID", "Drug: Tiotropium Respimat 5mcg QD", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Mometasone 220mcg BID", "description": "Mometasone is an ICS", "armGroupLabels": ["Mometasone then Placebo then Tiotropium", "Mometasone then Tiotropium then Placebo", "Placebo then Mometasone then Tiotropium", "Placebo then Tiotropium then Mometasone", "Tiotropium then Mometasone then Placebo", "Tiotropium then Placebo then Mometasone"], "otherNames": ["Asmanex"]}, {"type": "DRUG", "name": "Tiotropium Respimat 5mcg QD", "description": "Tiotropium is a LMA", "armGroupLabels": ["Mometasone then Placebo then Tiotropium", "Mometasone then Tiotropium then Placebo", "Placebo then Mometasone then Tiotropium", "Placebo then Tiotropium then Mometasone", "Tiotropium then Mometasone then Placebo", "Tiotropium then Placebo then Mometasone"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Mometasone then Placebo then Tiotropium", "Mometasone then Tiotropium then Placebo", "Placebo then Mometasone then Tiotropium", "Placebo then Tiotropium then Mometasone", "Tiotropium then Mometasone then Placebo", "Tiotropium then Placebo then Mometasone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1.", "description": "This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of treatment failures. If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.", "timeFrame": "End of 12-week treatment period"}], "secondaryOutcomes": [{"measure": "Treatment Failure", "description": "Treatment Failure includes:\n\n* Awakening from asthma three or more times in a two-week period or on two consecutive nights, or\n* Using albuterol for relief of symptoms four or more times/day for two or more consecutive days, or\n* Albuterol has been relieving symptoms for less than four hours after each treatment over a 12-hour period, or\n* Using albuterol for relief of symptoms daily for seven days, and this use exceeds two times the weekly use of albuterol in the baseline period, or\n* exercise induces unusual breathlessness", "timeFrame": "End of 12-week treatment period"}, {"measure": "Annualized Asthma Control Days", "description": "Asthma Control Days (ACD) are based on patient completed electronic daily diaries, and are defined as: A day with no rescue albuterol use (pre-exercise albuterol will not be counted), no non-study asthma medications, no daytime asthma symptoms (shortness of breath, wheezing, chest tightness, phlegm/mucus rated as mild, moderate or severe, or cough rated as moderate or severe), no nighttime asthma symptoms, no unscheduled healthcare visits for asthma, and no PEF \\< 80% of predetermined baseline. Annualized ACD are calculated as the proportion of ACD during the treatment period multiplied by 365.", "timeFrame": "End of 12-week treatment period"}, {"measure": "Forced Expiratory Volume at One Second (FEV1) Percent of Predicted", "description": "FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.", "timeFrame": "End of 12-week treatment period"}, {"measure": "Peak Expiratory Flow Rate", "description": "Peak expiratory flow rate is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways.", "timeFrame": "End of 12-week treatment period"}, {"measure": "Asthma Exacerbations", "description": "Asthma exacerbations are more severe episodes of acute worsening, defined by meeting one or more of the following:\n\n* FEV1 \\<50% of baseline on 2 consecutive measurements\n* FEV1 \\<40% of predicted on 2 consecutive measurements\n* Use of \u2265 16 puffs of \"as needed\" \u03b2-agonist per 24 hours for a period of 48 hours\n* Use of oral/parenteral corticosteroid due to asthma", "timeFrame": "End of 12-week treatment period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Physician-diagnosed asthma for at least previous 12 months.\n* Able to perform reproducible spirometry.\n* Baseline FEV1\u226570% of predicted.\n* Asthma confirmed either by:\n\n  * Beta-agonist reversibility to 4 puffs albuterol \u2265 12% OR\n  * Methacholine PC20 \u2264 16 mg/ml\n* At least 1 of the following indications for chronic controller therapy:\n\n  * Asthma Symptoms \\> 2 days/week OR\n  * Nocturnal Asthma Symptoms \\> 2 nights/month OR\n  * Short-acting beta-agonist use for symptom control \\> 2 days/week\n* For participants \u226518 years of age: Ability to provide informed consent. For participants under 18 years of age: Ability to provide verbal or written assent and ability of parent to provide informed consent.\n* Willingness, if female and able to conceive, to utilize one medically-acceptable form of contraception.\n\nExclusion Criteria:\n\n* Chronic inhaled or oral corticosteroid therapy.\n* Use of inhaled or oral corticosteroid therapy within 6 weeks.\n* New allergen immunotherapy within the past 3 months or anticipated changes to an ongoing immunotherapy regimen.\n* Use of omalizumab within 3 months.\n* History of:\n\n  * bladder-neck obstruction, urinary retention or benign prostatic hyperplasia\n  * narrow angle glaucoma\n  * significant cardiovascular disorders and arrhythmias\n  * life-threatening asthma requiring treatment with intubation or mechanical ventilation within the past 5 years\n* Respiratory tract infection within past 6 weeks.\n* History of smoking within the past 1 year, or \\> 10 pack-years total if \u2265 18 years of age, or \\> 5 pack-years total if \\< 18 years of age.\n* Chronic diseases or medical conditions (other than asthma) that could put the participant at risk by participation, e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, endocrine or nervous system, or immunodeficiency.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "William Busse, M.D.", "affiliation": "University of Wisconsin, Madison", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Arizona College of Medicine", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "UCSF Benioff Children's Hospital", "city": "San Francisco", "state": "California", "zip": "94143", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "University of California at San Francisco", "city": "San Francisco", "state": "California", "zip": "94143", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "National Jewish Health", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Nemours Children's Clinic", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Nemours Children's Clinic", "city": "Orlando", "state": "Florida", "zip": "32827", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Northwestern Memorial Hospital", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Rush University Medical Center", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Illinois at Chicago", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Ann and Robert H. Lurie Children's Hospital", "city": "Chicago", "state": "Illinois", "zip": "60614", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Chicago", "city": "Chicago", "state": "Illinois", "zip": "60637", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Children's Hospital Boston", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "St. Louis Children's Hospital", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Columbia University Medical Center", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Duke University School of Medicine", "city": "Durham", "state": "North Carolina", "zip": "27110", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "North Carolina Clinical Research", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Wake Forest University Health Sciences", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Rainbow Babies and Children's Hospital, Case Western Reserve University", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Allegheny General Hospital", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "University of Pittsburgh", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Children's Hospital of Pittsburgh of UPMC", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15224", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "University of Wisconsin-Madison", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "31112384", "type": "DERIVED", "citation": "Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19."}, {"pmid": "30593883", "type": "DERIVED", "citation": "Sorkness CA, King TS, Dyer AM, Chinchilli VM, Mauger DT, Krishnan JA, Blake K, Castro M, Covar R, Israel E, Kraft M, Lang JE, Lugogo N, Peters SP, Wechsler ME, Wenzel SE, Lazarus SC; National Heart Lung and Blood Institute's \"AsthmaNet\". Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. Contemp Clin Trials. 2019 Feb;77:98-103. doi: 10.1016/j.cct.2018.12.012. Epub 2018 Dec 27."}], "seeAlsoLinks": [{"label": "AsthmaNet", "url": "http://asthmanetresearch.org/"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Mometasone Then Tiotropium Then Placebo", "description": "Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "FG001", "title": "Mometasone Then Placebo Then Tiotropium", "description": "Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "FG002", "title": "Placebo Then Mometasone Then Tiotropium", "description": "Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "FG003", "title": "Placebo Then Tiotropium Then Mometasone", "description": "Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "FG004", "title": "Tiotropium Then Placebo Then Mometasone", "description": "Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "FG005", "title": "Tiotropium Then Mometasone Then Placebo", "description": "Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "48"}, {"groupId": "FG002", "numSubjects": "50"}, {"groupId": "FG003", "numSubjects": "51"}, {"groupId": "FG004", "numSubjects": "47"}, {"groupId": "FG005", "numSubjects": "50"}]}, {"type": "Completed 1st Period", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "47"}, {"groupId": "FG002", "numSubjects": "45"}, {"groupId": "FG003", "numSubjects": "48"}, {"groupId": "FG004", "numSubjects": "46"}, {"groupId": "FG005", "numSubjects": "45"}]}, {"type": "Completed 2nd Period", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "41"}, {"groupId": "FG002", "numSubjects": "41"}, {"groupId": "FG003", "numSubjects": "46"}, {"groupId": "FG004", "numSubjects": "42"}, {"groupId": "FG005", "numSubjects": "41"}]}, {"type": "Completed 3rd Period", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "40"}, {"groupId": "FG003", "numSubjects": "45"}, {"groupId": "FG004", "numSubjects": "38"}, {"groupId": "FG005", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "40"}, {"groupId": "FG003", "numSubjects": "45"}, {"groupId": "FG004", "numSubjects": "38"}, {"groupId": "FG005", "numSubjects": "38"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "8"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants", "groups": [{"id": "BG000", "title": "Mometasone Then Tiotropium Then Placebo", "description": "Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "BG001", "title": "Mometasone Then Placebo Then Tiotropium", "description": "Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "BG002", "title": "Placebo Then Mometasone Then Tiotropium", "description": "Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "BG003", "title": "Placebo Then Tiotropium Then Mometasone", "description": "Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "BG004", "title": "Tiotropium Then Placebo Then Mometasone", "description": "Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "BG005", "title": "Tiotropium Then Mometasone Then Placebo", "description": "Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo\n\nMometasone 220mcg BID: Mometasone is an ICS\n\nTiotropium Respimat 5mcg QD: Tiotropium is a LMA\n\nPlacebo"}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "50"}, {"groupId": "BG003", "value": "51"}, {"groupId": "BG004", "value": "47"}, {"groupId": "BG005", "value": "50"}, {"groupId": "BG006", "value": "295"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.3", "spread": "15.3"}, {"groupId": "BG001", "value": "32.6", "spread": "13.8"}, {"groupId": "BG002", "value": "33.2", "spread": "13.9"}, {"groupId": "BG003", "value": "30.0", "spread": "14.8"}, {"groupId": "BG004", "value": "30.8", "spread": "12.5"}, {"groupId": "BG005", "value": "28.2", "spread": "12.9"}, {"groupId": "BG006", "value": "31.2", "spread": "13.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "33"}, {"groupId": "BG004", "value": "27"}, {"groupId": "BG005", "value": "33"}, {"groupId": "BG006", "value": "184"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "18"}, {"groupId": "BG004", "value": "20"}, {"groupId": "BG005", "value": "17"}, {"groupId": "BG006", "value": "111"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "7"}, {"groupId": "BG006", "value": "35"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "44"}, {"groupId": "BG004", "value": "40"}, {"groupId": "BG005", "value": "43"}, {"groupId": "BG006", "value": "260"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "2"}, {"groupId": "BG006", "value": "11"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "14"}, {"groupId": "BG005", "value": "16"}, {"groupId": "BG006", "value": "88"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "33"}, {"groupId": "BG003", "value": "31"}, {"groupId": "BG004", "value": "32"}, {"groupId": "BG005", "value": "30"}, {"groupId": "BG006", "value": "192"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "2"}, {"groupId": "BG006", "value": "4"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "50"}, {"groupId": "BG003", "value": "51"}, {"groupId": "BG004", "value": "47"}, {"groupId": "BG005", "value": "50"}, {"groupId": "BG006", "value": "295"}]}]}]}, {"title": "Forced expiratory volume at one second (FEV1) Percent of Predicted", "description": "FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of predicted FEV1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.6", "spread": "11.5"}, {"groupId": "BG001", "value": "91.5", "spread": "11.2"}, {"groupId": "BG002", "value": "92.0", "spread": "11.8"}, {"groupId": "BG003", "value": "93.8", "spread": "12.4"}, {"groupId": "BG004", "value": "91.7", "spread": "13.6"}, {"groupId": "BG005", "value": "91.6", "spread": "12.5"}, {"groupId": "BG006", "value": "91.9", "spread": "12.1"}]}]}]}, {"title": "Asthma Control Test", "description": "Measure Description: Asthma Control Test: The score is calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "21.3", "spread": "2.3"}, {"groupId": "BG001", "value": "21.2", "spread": "2.5"}, {"groupId": "BG002", "value": "21.1", "spread": "2.7"}, {"groupId": "BG003", "value": "20.9", "spread": "2.2"}, {"groupId": "BG004", "value": "20.9", "spread": "2.8"}, {"groupId": "BG005", "value": "21.1", "spread": "2.5"}, {"groupId": "BG006", "value": "21.1", "spread": "2.5"}]}]}]}, {"title": "Sputum differential count - Percent eosinophils", "description": "Percentage of cells collected from induced sputum that are eosinophils", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "percentage of cells", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.1", "lowerLimit": "0.0", "upperLimit": "0.4"}, {"groupId": "BG001", "value": "0.4", "lowerLimit": "0.0", "upperLimit": "1.7"}, {"groupId": "BG002", "value": "0.4", "lowerLimit": "0.0", "upperLimit": "2.4"}, {"groupId": "BG003", "value": "0.2", "lowerLimit": "0.0", "upperLimit": "1.0"}, {"groupId": "BG004", "value": "0.2", "lowerLimit": "0.0", "upperLimit": "0.7"}, {"groupId": "BG005", "value": "0.2", "lowerLimit": "0.0", "upperLimit": "0.8"}, {"groupId": "BG006", "value": "0.2", "lowerLimit": "0.0", "upperLimit": "1.0"}]}]}]}, {"title": "Blood differential count - Percent eosinophils", "description": "Percentage of blood cells that are eosinophils", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "percentage of cells", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.3", "lowerLimit": "1.1", "upperLimit": "4.1"}, {"groupId": "BG001", "value": "4.0", "lowerLimit": "2.0", "upperLimit": "5.3"}, {"groupId": "BG002", "value": "3.0", "lowerLimit": "1.9", "upperLimit": "4.7"}, {"groupId": "BG003", "value": "3.2", "lowerLimit": "2.0", "upperLimit": "5.0"}, {"groupId": "BG004", "value": "3.0", "lowerLimit": "1.5", "upperLimit": "5.0"}, {"groupId": "BG005", "value": "2.8", "lowerLimit": "1.0", "upperLimit": "4.0"}, {"groupId": "BG006", "value": "3.0", "lowerLimit": "1.7", "upperLimit": "5.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1.", "description": "This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of treatment failures. If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.", "populationDescription": "For each pairwise comparison (mometasone vs. placebo and tiotropium vs. placebo), participants were required to complete both of the relevant treatment periods in order to be included in the analysis.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "End of 12-week treatment period", "groups": [{"id": "OG000", "title": "Eosinophil Low", "description": "Participants with sputum eosinophils \\< 2% at study entry"}, {"id": "OG001", "title": "Eosinophil High", "description": "Participants with sputum eosinophils \\>= 2% at study entry"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Mometesone superior to placebo", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "35"}]}]}, {"title": "Placebo superior to mometasone", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "Mometesone equal to placebo", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "Tiotropium superior to placebo", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "62"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Placebo superior to tiotropium", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "62"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Tiotropium equal to placebo", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "62"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "18"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that, among those participants for which either mometasone is not equal to placebo, the proportion for which mometasone is superior to placebo is equal to the proportion for which placebo is superior to mometasone. The trial was designed to provide power of 0.85 for a 0.20 difference between the proportions being compared at a significance level of 0.025.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.14", "statisticalMethod": "exact binomial test", "statisticalComment": "a priori threshold for significance was 0.025"}, {"groupIds": ["OG000"], "groupDescription": "The null hypothesis was that, among those participants for which either tiotropium is not equal to placebo, the proportion for which tiotropium is superior to placebo is equal to the proportion for which placebo is superior to tiotropium. The trial was designed to provide power of 0.85 for a 0.20 difference between the proportions being compared at a significance level of 0.025.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.029", "pValueComment": "a priori threshold for significance was 0.025", "statisticalMethod": "exact binomial test"}, {"groupIds": ["OG001"], "groupDescription": "The null hypothesis was that, among those participants for which either mometasone is not equal to placebo, the proportion for which mometasone is superior to placebo is equal to the proportion for which placebo is superior to mometasone. This was an exploratory analysis and there were no power considerations.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.001", "pValueComment": "this analysis is considered exploratory", "statisticalMethod": "exact binomial test"}, {"groupIds": ["OG001"], "groupDescription": "The null hypothesis was that, among those participants for which either tiotropium is not equal to placebo, the proportion for which tiotropium is superior to placebo is equal to the proportion for which placebo is superior to tiotropium. This was an exploratory analysis and there were no power considerations.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.45", "pValueComment": "this analysis is considered exploratory", "statisticalMethod": "exact binomial test"}]}, {"type": "SECONDARY", "title": "Treatment Failure", "description": "Treatment Failure includes:\n\n* Awakening from asthma three or more times in a two-week period or on two consecutive nights, or\n* Using albuterol for relief of symptoms four or more times/day for two or more consecutive days, or\n* Albuterol has been relieving symptoms for less than four hours after each treatment over a 12-hour period, or\n* Using albuterol for relief of symptoms daily for seven days, and this use exceeds two times the weekly use of albuterol in the baseline period, or\n* exercise induces unusual breathlessness", "populationDescription": "participants who completed the treatment period with data to evaluate treatment failure outcome", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "End of 12-week treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "The placebo treatment period for all participants."}, {"id": "OG001", "title": "Mometasone 220mcg BID", "description": "The mometasone treatment period for all participants. Mometasone administered 220mcg BID"}, {"id": "OG002", "title": "Tiotropium Respimat 5mcg QD", "description": "The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "254"}, {"groupId": "OG001", "value": "255"}, {"groupId": "OG002", "value": "258"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "35"}]}]}]}, {"type": "SECONDARY", "title": "Annualized Asthma Control Days", "description": "Asthma Control Days (ACD) are based on patient completed electronic daily diaries, and are defined as: A day with no rescue albuterol use (pre-exercise albuterol will not be counted), no non-study asthma medications, no daytime asthma symptoms (shortness of breath, wheezing, chest tightness, phlegm/mucus rated as mild, moderate or severe, or cough rated as moderate or severe), no nighttime asthma symptoms, no unscheduled healthcare visits for asthma, and no PEF \\< 80% of predetermined baseline. Annualized ACD are calculated as the proportion of ACD during the treatment period multiplied by 365.", "populationDescription": "participants who completed the treatment period with data to evaluate asthma control days", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "End of 12-week treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "The placebo treatment period for all participants"}, {"id": "OG001", "title": "Mometasone 220mcg BID", "description": "The mometasone treatment period for all participants. Mometasone administered 220mcg BID"}, {"id": "OG002", "title": "Tiotropium Respimat 5mcg QD", "description": "The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "216"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "228"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "179", "spread": "137"}, {"groupId": "OG001", "value": "186", "spread": "141"}, {"groupId": "OG002", "value": "176", "spread": "139"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume at One Second (FEV1) Percent of Predicted", "description": "FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.", "populationDescription": "participants who completed the treatment period and were able to provide FEV1 measurements", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "End of 12-week treatment period", "groups": [{"id": "OG000", "title": "Eosinophil Low - Placebo", "description": "The placebo treatment period for all participants"}, {"id": "OG001", "title": "Mometasone 220mcg BID", "description": "The mometasone treatment period for all participants. Mometasone administered 220mcg BID"}, {"id": "OG002", "title": "Tiotropium Respimat 5mcg QD", "description": "The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "254"}, {"groupId": "OG001", "value": "247"}, {"groupId": "OG002", "value": "252"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92", "spread": "14"}, {"groupId": "OG001", "value": "94", "spread": "13"}, {"groupId": "OG002", "value": "95", "spread": "14"}]}]}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow Rate", "description": "Peak expiratory flow rate is a person's maximum speed of expiration. It measures the airflow through the bronchi and thus the degree of obstruction in the airways.", "populationDescription": "participants who completed the treatment period and were able to provide FEV1 measurements", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters per minute", "timeFrame": "End of 12-week treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "The placebo treatment period for all participants"}, {"id": "OG001", "title": "Mometasone 220mcg BID", "description": "The mometasone treatment period for all participants. Mometasone administered 220mcg BID"}, {"id": "OG002", "title": "Tiotropium Respimat 5mcg QD", "description": "The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "249"}, {"groupId": "OG002", "value": "256"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "476", "spread": "117"}, {"groupId": "OG001", "value": "485", "spread": "117"}, {"groupId": "OG002", "value": "497", "spread": "117"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Exacerbations", "description": "Asthma exacerbations are more severe episodes of acute worsening, defined by meeting one or more of the following:\n\n* FEV1 \\<50% of baseline on 2 consecutive measurements\n* FEV1 \\<40% of predicted on 2 consecutive measurements\n* Use of \u2265 16 puffs of \"as needed\" \u03b2-agonist per 24 hours for a period of 48 hours\n* Use of oral/parenteral corticosteroid due to asthma", "populationDescription": "participants who completed the treatment period with data to evaluate exacerbations", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "End of 12-week treatment period", "groups": [{"id": "OG000", "title": "Placebo", "description": "The placebo treatment period for all participants"}, {"id": "OG001", "title": "Mometasone 220mcg BID", "description": "The mometasone treatment period for all participants. Mometasone administered 220mcg BID"}, {"id": "OG002", "title": "Tiotropium Respimat 5mcg QD", "description": "The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "254"}, {"groupId": "OG001", "value": "255"}, {"groupId": "OG002", "value": "258"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Each participant was followed over the course of three 12-week treatment periods for a total of 36 weeks. The adverse events recorded below are reported at the treatment period level and represent 12 weeks of \"at risk\" exposure time.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "The placebo treatment period for all participants", "deathsNumAffected": 0, "deathsNumAtRisk": 276, "seriousNumAffected": 0, "seriousNumAtRisk": 276, "otherNumAffected": 45, "otherNumAtRisk": 276}, {"id": "EG001", "title": "Mometasone 220mcg BID", "description": "The mometasone treatment period for all participants. Mometasone administered 220mcg BID", "deathsNumAffected": 0, "deathsNumAtRisk": 275, "seriousNumAffected": 6, "seriousNumAtRisk": 275, "otherNumAffected": 47, "otherNumAtRisk": 275}, {"id": "EG002", "title": "Tiotropium Respimat 5mcg QD", "description": "The tiotropium treatment period for all participants. Tiotropium administered 5mcg QD", "deathsNumAffected": 0, "deathsNumAtRisk": 271, "seriousNumAffected": 2, "seriousNumAtRisk": 271, "otherNumAffected": 38, "otherNumAtRisk": 271}], "seriousEvents": [{"term": "pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 271}]}, {"term": "closed fracture of lower end of humerus", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 271}]}, {"term": "Partial bowel obstruction.", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 271}]}, {"term": "Hydatidiform mole", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 271}]}, {"term": "Unspecified nonpsychotic mental disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "ICS-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 271}]}, {"term": "Adjustment disorder with depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 271}]}, {"term": "malignant neoplasm of skin of other and unspecified parts of face", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 271}]}, {"term": "Acute appendicitis without mention of peritonitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 271}]}], "otherEvents": [{"term": "Acute nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 42, "numAffected": 37, "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 38, "numAffected": 33, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 37, "numAffected": 29, "numAtRisk": 271}]}, {"term": "Acute URI not otherwise specified", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 276}, {"groupId": "EG001", "numEvents": 18, "numAffected": 16, "numAtRisk": 275}, {"groupId": "EG002", "numEvents": 13, "numAffected": 11, "numAtRisk": 271}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "David Mauger", "organization": "Penn State University", "email": "dmauger@psu.edu", "phone": "717-531-7178"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2015-11-12", "uploadDate": "2019-03-26T12:36", "filename": "Prot_SAP_000.pdf", "size": 1897747}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "At 3", "relevance": "HIGH"}, {"id": "M416", "name": "Tiotropium Bromide", "asFound": "Melanoma", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}